Macquarie views Crowdstrike’s acquisition of Bionic for $350 as a tuck-in technology acquisition that can accelerate CrowdStrike’s product development and deployment, the analyst tells investors in a research note. The firm made no change to its Outperform rating or $180 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRWD: